Long-term immunogenicity of a single-dose live recombinant chimeric Japanese encephalitis vaccine in adults.

ABSTRACT:

Background

Japanese encephalitis virus is a leading cause of viral encephalitis in Asia, with high case-fatality rate and morbidity. Although the live recombinant Japanese encephalitis chimeric vaccine (Imojev®) offers strong initial immunity, data on long-term efficacy beyond 5 years remain limited.

Methods

We conducted a cross-sectional study on adults vaccinated with Imojev® at a specialist travel clinic in Brisbane, Australia. Participants were stratified based on the time since vaccination: 2-5 years and >5 years. Neutralizing antibody titres were measured using the plaque reduction neutralization test (PRNT50), with titres ≥10 indicating seropositivity.

Results

Of the 103 participants, 47 were vaccinated 2-5 years prior and 56 were vaccinated ≥5 years prior to e

SUBMITTER: Mills DJ 

PROVIDER: S-EPMC11896838 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature